RECAPTURE OF RESPONSE WITH OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO WITHDREW THERAPY: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Anita Afzali  1     Michael Chiorean  2     Garrett Lawlor  3     Mark T. Osterman  3     Arteid Memaj  3     Remo Panaccione  4     Subrata Ghosh  5    
1 The Ohio State University Wexner Medical Center, Columbus, United States
2 Swedish Medical Group, Seattle, United States
3 Bristol Myers Squibb, Princeton, United States
4 Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Canada
5 College of Medicine and Health, University College Cork, Cork, Ireland

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing